Why is rinvoq so expensive?

Rinvoq (upadacitinib) is expensive for a few common reasons in the specialty-drug world:

• It’s a biologic/specialty “newer” oral targeted medicine: Rinvoq is a branded drug (not generic for most people yet). Branded specialty drugs typically carry high prices because they’re still under patent/protection and are aimed at specific inflammatory/autoimmune diseases.
• High R&D and trial costs: Developing drugs that target specific immune pathways (like JAK inhibition) requires large clinical trials and years of investment, which gets reflected in the price.
• Manufacturing and regulatory costs: Specialty drugs also involve costly quality controls, safety monitoring requirements, and ongoing post‑marketing studies.
• Market exclusivity + limited competition: If there aren’t many comparable alternatives covered in the same way, manufacturers have more pricing power.
• Insurance setup and pharmacy reimbursement: What you pay is often heavily influenced by your insurance formulary, copay/coinsurance structure, deductibles, prior authorization requirements, and whether a patient assistance program applies. Two people paying “the same” drug can have very different out-of-pocket costs.

If you tell me your country, whether you’re paying cash vs insurance, and what your insurance plan type is (commercial, Medicare/Part D, Medicaid, etc.), I can suggest the most likely reasons in your specific case and options to lower the cost (copay cards, prior auth help, manufacturer assistance, or therapeutic alternatives).